MoonLake Immunotherapeutics
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$244.8 | -$143.1 | -$54.1 | -$65.1 | -$4.6 |
| Net income | -$227.3 | -$118.9 | -$36.0 | -$50.0 | -$4.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$196.0 | -$117.1 | -$43.1 | -$55.9 | — |
| Share repurchases | — | $<0.1 | $0.0 | $0.0 | — |
Shares outstanding 85.1M · Free float 71.9%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.